Nova Eye Medical, trading on the OTCMKTS under the symbol ELXMF, is a clinical-stage biopharmaceutical company dedicated to the development of novel, cell-based therapies for the treatment of debilitating eye diseases. The company concentrates its research on regenerative medicine approaches aimed at restoring vision by repairing or replacing damaged retinal and ocular tissues. Nova Eye Medical’s pipeline includes both autologous and allogeneic cell therapy candidates designed to address conditions such as age-related macular degeneration, diabetic retinopathy, and other retinopathies.
The company’s lead programs leverage proprietary techniques to isolate, expand, and deliver therapeutic cells directly to the subretinal space or vitreous cavity. These investigational products are engineered to secrete neurotrophic factors, modulate inflammation, and promote tissue repair. Nova Eye Medical has advanced multiple candidates through preclinical development and into early-stage clinical trials, working to establish safety, tolerability, and preliminary efficacy in patients suffering from vision loss.
Headquartered in Fort Lauderdale, Florida, Nova Eye Medical serves patient populations across the United States and is pursuing regulatory pathways in key international markets, including Europe and Asia. The company collaborates with academic medical centers and contract research organizations to conduct clinical studies, and it maintains partnerships with institutions specializing in ophthalmology and regenerative medicine. By integrating translational science with clinical expertise, Nova Eye Medical seeks to accelerate the availability of its therapies to the global eye‐care community.
Founded in 2013, Nova Eye Medical is led by President and Chief Executive Officer Frank Hammond, who brings over two decades of experience in life-science commercialization. The executive team includes seasoned professionals in clinical development, manufacturing, and regulatory affairs, supported by a board of directors with deep expertise in biotechnology and ophthalmology. Together, they guide the company’s strategy to deliver transformative treatments for patients experiencing vision impairment and blindness.
AI Generated. May Contain Errors.
Free ELXMF Stock Alerts